Next Article in Journal
Anti-Tumour Promoting Activity and Antioxidant Properties of Girinimbine Isolated from the Stem Bark of Murraya koenigii S.
Previous Article in Journal
An Improved Synthesis of Pentacene: Rapid Access to a Benchmark Organic Semiconductor
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 17
Issue 4
10.3390/molecules17044634
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis and Antibacterial Evaluation of New N-acylhydrazone Derivatives from Dehydroabietic Acid

by
Wen Gu
*,
Rongrong Wu
,
Shilong Qi
,
Chenhai Gu
,
Fanjunnan Si
and
Zhuhui Chen
College of Chemical Engineering, Nanjing Forestry University, Nanjing 210037, China
*
Author to whom correspondence should be addressed.
Molecules 2012, 17(4), 4634-4650; https://doi.org/10.3390/molecules17044634
Submission received: 26 March 2012 / Revised: 1 April 2012 / Accepted: 5 April 2012 / Published: 20 April 2012
Browse Figures
Versions Notes

Abstract

:
A series of new N-acylhydrazone derivatives were synthesized in good yields through the reactions of dehydroabietic acid hydrazide with a variety of substituted arylaldehydes. The structures of the synthesized compounds were confirmed by IR, 1H- and 13C-NMR, ESI-MS, elemental analysis and single crystal X-ray diffraction. From the crystal structure of compound 4l, the C=N double bonds of these N-acylhydrazones showed (E)-configuration, while the NMR data of compounds 4a–q indicated the existence of two rotamers for each compound in solution. The target compounds were evaluated for their antibacterial activities against four microbial strains. The result suggested that several compounds exhibited pronounced antibacterial activities. Particularly, compound 4p exhibited good antibacterial activity against Staphylococcus aureus and Bacillus subtilis comparable to positive control. The possible antibacterial metabolism and the strategy for further optimization of this compound were also discussed.

1. Introduction

Microbial infections remain a pressing human health problem because of a combination of factors, including emerging infectious diseases and the rapid development of multi-drug resistance pathogens worldwide [1,2]. In spite of many antibiotics and chemotherapeutics available, there will still be a vital need to discover new and effective antimicrobial agents. In recent years, the N-acylhydrazone moiety has proved to be an important pharmacophore structure in pharmaceutical research [3]. These structures have received much attention due to their chemotherapeutic potential in the development of novel antimicrobial agents [4,5]. Some widely used antibacterial drugs such as furacilin, furazolidone and ftivazide are known to contain such kind of moieties [6]. In addition, many N-acylhydrazone derivatives have been reported to exhibit an array of biological activities such as antimalarial [7], antiviral [8], antitumor [9], anti-inflammatory [10], anticonvulsant [11], antidepressant [12] and vasodilative activities [13].
Naturally occurring diterpenoids with an abietane skeleton are often discovered and isolated from higher plants and their diverse bioactivities have been reported [14,15]. Among them, dehydroabietic acid (DHA, 1) is one of the major tricyclic diterpenoid constituents of pine resin and can be readily obtained from commercial disproportionated rosin. DHA and its derivatives have exhibited a broad spectrum of biological activities such as antimicrobial, antitumor, antiviral, antioxidant, anti-inflammatory and gastroprotective activities [16,17,18,19,20,21], which indicate that the compound is a potentially useful starting material for the synthesis of industrially or pharmacologically important products. In view of these findings, it would be worthwhile to design, synthesize new derivatives of DHA bearing N-acylhydrazone moiety and evaluate their potential antimicrobial activities. In continuation of our previous study on new antimicrobial derivatives of resin acids [22], we report herein the synthesis and characterization of a series of new N-acylhydrazones starting from DHA. Their in vitro antibacterial activities against several test microbes are also presented.

2. Results and Discussion

2.1. Synthesis

The synthetic procedures for the target compounds 4a–q are outlined in Scheme 1. The key intermediate dehydroabietic acid hydrazide (3) was synthesized by hydrazination of dehydroabietate chloride (2), which was prepared by the reaction of dehydroabietic acid (1) with thionyl chloride [23]. In the former literature, the synthesis of hydrazides was usually carried out by hydrazination of methyl/ethyl esters of the corresponding carboxylic acids [24,25]. However, in this case, it was found that ethyl dehydroabietate could hardly be converted to the hydrazide 3, possibly because of the low reactivity of the ester or the steric hindrance caused by the adjacent moieties of the molecule [26]. Alternatively the hydrazide could be synthesized in good yield from dehydroabietate chloride (2) with higher reactivity. Then the hydrazide 3 was condensed with different substituted aromatic aldehydes in refluxing ethanol to afford the corresponding N-acylhydrazones 4a–q in good yield.

2.2. Structural Analysis

The structures of the synthesized N-acylhydrazone derivatives were confirmed on the basis of IR, MS, NMR, elemental analysis and crystallographic methods. The IR spectra of 4a–q exhibited in all cases N-H bands in the range 3,232–3,279 cm−1. The strong absorption bands at 1,646–1,658 cm−1 were due to the C=O stretch vibrations of the hydrazone moieties. The ESI-MS of compounds 4a–q displayed, in all cases, quasimolecular ion peaks which confirmed their molecular weights. The 1H-NMR spectra of compounds 4a–q were similar except for the aromatic protons. In a typical example, 1H-NMR spectra of 4a showed a doublet at δ 1.22 (1.20) ppm corresponding to six methyl protons (H-18 and H-19) of the isopropyl group, together with a muliplet at δ 2.82 (2.78) ppm due to the vicinal CH proton (H-17). Two singlets at δ 1.25 (1.24) and 1.40 (1.34) ppm could be assigned to methyl protons at C-16 and C-15, respectively. Resonance peaks attributing to eight aromatic protons in the two benzene rings appeared in the range δ 6.82–7.88 ppm. Among them, two doublets coupled with each other at δ 7.00 (6.95) and 7.16 (7.08) ppm could be assigned to H-12 and H-11, respectively. The singlet at δ 6.87 (6.82) ppm was due to the signal of H-14. Because of the symmetry of monosubstituted benzene ring, the signals of H-2′ and H-6′ appeared as a doublet at δ 7.72 (7.88) ppm, while the signals at δ 7.38–7.52 ppm could be assigned to H-3′, H-4′ and H-5′. The N=CH proton appeared as a singlet at δ 8.21 (8.03) ppm, and the amide NH proton resonated as a broad singlet at δ 8.83 (9.29) ppm. In the 13C-NMR spectra, the signal at δ 23.9 (23.8) ppm could be assigned to C-18 and C-19. The carbon atoms of the two benzene rings resonated as ten pairs of absoption peaks because of the symmetry of substituent. In addition, the peaks at δ 146.1 (145.8) and 175.2 (176.8) ppm could be attributed to the signals of C=N and C=O carbons, respectively. The 1H- and 13C-NMR signals of other N-acylhydrazones were assigned by comparing with those of 4a.
Molecules 17 04634 g001 550
Scheme 1. Synthetic route of hydrazone derivatives (4a–q) from dehydroabietic acid.
Scheme 1. Synthetic route of hydrazone derivatives (4a–q) from dehydroabietic acid.
Molecules 17 04634 g001
Interestingly, in their 1H-NMR spectra, there were, if discriminable, two sets of signals observed for all groups, which resulted from the equilibrium and interconversion between rotamers (and/or configurational isomers) of each compound in solution [27,28]. It was known that N-acylhydrazones may exist in four possible forms in respect to (E/Z)-configurational isomers relative to the C=N double bonds and (E′/Z′)-rotamers caused by the inversion of amide bonds (Figure 1). However, the E/Z isomerization was not observed since these N-acylhydrazones exist primarily or completely in the (E)-configuration because of the steric hindrance relative to the moiety [29], which was supported by means of relative free energy calculations in a former report [30]. As for the characteristic peaks of N-acylhydrazones, the N=CH protons appeared as expected as two separate singlets in the region δ 7.71–8.58 ppm. The amide inversion also made the CONH proton present as two broad singlets in the range δ 8.71–10.18 ppm.
Molecules 17 04634 g002 550
Figure 1. For possible forms of N-acylhydrazone derivatives.
Figure 1. For possible forms of N-acylhydrazone derivatives.
Molecules 17 04634 g002
The single crystal of the representative compound 4l was recrystallized from ethanol for the X-ray diffraction to confirm the configuration. The crystal data of 4l are presented in Table 1, and its ORTEP drawing with the atom numbering scheme is shown in Figure 2. In accordance with starting material dehydroabietic acid, the two cyclohexane ring A (C1~C6) and B (C5~C10) bearing chair and half-chair conformations, respectively, show a trans ring junction, with two methyl groups of C15 and C16 in the axial positions. The molecule displays an E configuration with respect to the N2=C21 double bond with a N1-N2-C21-C22 torsion angle of 179.5(3)°, and a Z′ conformation due to the amide bond with a N2-N1-C20-O1 torsion angle of 1.4(6)°.
Table
Table 1. Crystal structure data for compound 4l.
Table 1. Crystal structure data for compound 4l.
Empirical formulaC29H38ClN3O4F(0 0 0)1128
Formula weight528.07θ range for data collection (°)1.93–25.38
Temperature (K)293(2)Max. and min. transmission0.9674 and 0.9516
Crystal size (mm3)0.30 × 0.20 × 0.20Index ranges0 ≤ h ≤ 15
Crystal systemOrthorhombic 0 ≤ k ≤ 15
Space groupP212121 −21 ≤ l ≤ 21
a (Å)12.537(3)Reflectons collected5870
b (Å)13.097(3)Independent reflections5374
c (Å)17.855(4)Rint0.0253
α (°)90Data/restraints/parameters5374/3/328
β (°)90Goodness-of-fit on F21.001
γ (°)90R1, wR2 [I > 2σ(I)]0.0592/0.1567
V (Å3)2931.7(10)R1, wR2 (all data)0.0912/0.1783
Z4Flack parameter−0.09(13)
Dx (g/cm−3)1.196(Δρ)max (eÅ−3)0.520
μ (mm−1)0.167(Δρ)min (eÅ−3)−0.373
Molecules 17 04634 g003 550
Figure 2. Crystal structure of compound 4l.
Figure 2. Crystal structure of compound 4l.
Molecules 17 04634 g003

2.3. Antibacterial Activity

The synthesized compounds 3 and 4a–q were evaluated for their antibacterial activities against four bacterial strains. The minimal inhibitory concentration (MIC) values of these compounds against the test microorganisms were listed in Table 2. Also included were the MICs of positive control amikacin. The result revealed that the MICs of the tested compounds differed greatly ranging from 1.9 to >100 μg/mL. It was found that compounds 4c, 4d, 4l–n and 4p exhibited significant activities (1.9–7.8 μg/mL) against Gram-positive bacteria (S. aureus and B. subtilis). Among them, compound 4p showed the strongest activities against S. aureus and B. subtilis with MIC values (1.9 μg/mL) comparable to those of amikacin. Compounds 4l, 4n and 4p also showed strong inhibitions (3.9–7.8 μg/mL) against the Gram-negative strains Escherichia coli and Pseudomonas fluorescens. In addition, compounds 3, 4a, 4e, 4g, 4h and 4k exhibited moderate activities (15.6–31.2 μg/mL) against at least one strain of the four bacteria, while 4b, 4f, 4i, 4j, 4o and 4q showed marginal or no inhibitions against the four strains.
According to structure-activity relationships (SAR) studies, it could be concluded that different substitutions on aromatic rings affected drastically the antibacterial activities of the synthesized compounds. Compounds with electron-withdrawing substituents (halo and nitro) in the aromatic ring showed greater antibacterial activities than those with electron-donating groups (methyl and methoxy). The results of antibacterial assay indicated that the introduction of the halogen atom at 4′-position generally increased antibacterial activity, particularly F and Cl atoms, and compound 4n with 3′-Cl substituent also showed marked antibacterial activity. Previous literatures revealed that the introduction of halogen atoms into the pharmacophore structure could, in many cases, be beneficial to antibacterial activity [31,32]. On the other hand, compounds 4l, 4m and 4p with NO2 substituents exhibited good activities against the test bacteria, indicating that the introduction of NO2 group was essential for the antibacterial activity of these compounds.
Some N-acylhydrazone derivatives with nitrophenyl and nitrofuranyl moieties have been reported to demonstrate pronounced antibacterial activities [33,34]. Among them, nifuroxazide, a notable example bearing nitrofuran moiety has been used as an intestinal antiseptic [34]. Previous investigations suggested that the possible antibacterial mechanism of these derivatives could be related to the reduction of the nitro group by microbial nitroreductase together with the formation of toxic intermediates such as nitro radical-anion, nitroso, hydroxylamine derivatives and/or reactive oxygen species [35,36]. However, enzymatic nitroreduction of nitrofurans has also been found in animal tissues, implying that toxic and mutagenic effects could also occur in mammalian cells [36]. A number of literatures demonstrated that some nitrofuran antibiotics such as nitrofurantoin and nitrofurazone showed mutagenic or carcinogenic effects on mammalian cells and tissues [36,37]. A prodrug strategy might give some clue to resolve this problem. The functional groups of a drug can be modified by chemical reactions such as esterification, amide formation, etc. to prepare a prodrug with better physico-chemical properties, which can be bioconverted to the parental drug in vivo. Some recent studies on the prodrugs of metronidazole and nitrofurazone suggested that the prodrug approach may increase the biological activity and decrease the genotoxicity of these nitro compounds by improving the physico-chemical properties [38]. In light of these findings, further derivatization of compound 4p such as the introduction of various groups on the benzene ring, together with the in-depth SAR study and mutagenic assay are still required.
Table
Table 2. Antibacterial activities of compounds 4a–q.
Table 2. Antibacterial activities of compounds 4a–q.
Test compoundsMinimum inhibitory concentration (μg/mL)
S. aureusB. subtilisE. coliP. fluorescens
331.231.262.531.2
4a31.262.5>10062.5
4b>10062.5>100>100
4c7.83.931.2>100
4d7.815.631.262.5
4e31.231.2>100>100
4f>10062.5>100>100
4g62.515.631.262.5
4h62.531.2>100>100
4i>100>100>100>100
4j>10062.5>100>100
4k15.615.631.215.6
4l3.93.915.67.8
4m7.83.915.631.2
4n3.97.815.67.8
4o>10062.5>100>100
4p1.91.97.83.9
4q62.5>100>100>100
Amikacin0.90.91.90.9

3. Experimental

3.1. General

Melting points were measured on an XT-4 apparatus (Taike Corp., Beijing, China) and were uncorrected. IR spectra were measured on a Nexus 870 FT-IR spectrometer. The ESI-MS spectra were recorded on a Mariner System 5304 mass spectrometer. 1H-NMR spectra were accomplished in CDCl3 on a Bruker AV-500 NMR spectrometer using TMS as internal standard. Elemental analyses were performed on a CHN-O-Rapid instrument and were within ±0.4% of the theoretical values. Reactions and the resulted products were monitored by TLC which was carried out on silica gel IB-F flexible sheets from Mallinckrodt Baker Inc., Germany and visualized in UV light (254 nm). Silica gel (300–400 mesh) for column chromatography was purchased from Qingdao Marine Chemical Factory, China. The reagents (chemicals), all being of A.R. grade, were purchased from Shanghai Chemical Reagent Company (Shanghai, China). The substituted aryl aldehydes were purchased from Alfa Aesar Co. (Tianjing, China). Disproportionated rosin was provided by Zhongbang Chemicals Co., Ltd. (Zhaoqing, China), from which dehydroabietic acid (1, 97%) was isolated according to the published method [39].

3.2. Crystallographic Studies

X-ray single-crystal diffraction data for compound 4l was collected on an Enraf-Nonius CAD-4 diffractometer at 293(2) K using MoKα radiation (λ = 0.71073 Å) by the ω scan mode. The structure was solved by direct methods using the SHELXS program of the SHELXTL package and refined by full-matrix least-squares methods with SHELXL [40]. All non-hydrogen atoms of compound 4l were refined with anisotropic thermal parameters. All hydrogen atoms were generated theoretically onto the parent atoms and refined with riding model position parameters and fixed isotropic thermal factors. CCDC 848482 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; Fax: +44-122-333-6033; E-Mail: deposit@ccdc.cam.ac.uk).

3.3. Chemistry

3.3.1. Dehydroabietic Acid Hydrazide (3)

SOCl2 (2.18 mL, 3.57 g, 0.03 mol) was added slowly to a solution of dehydroabietic acid (6 g, 0.02 mol) in benzene (20 mL). The mixture was then refluxed for 3 h. After cooling, the solvent and excess SOCl2 were removed in vacuo to yield dehydroabietate chloride (2) as a yellow oily product. The product was dissolved in CH2Cl2 (30 mL) and cooled to 0 °C, which was then added dropwise under stirring to a solution of hydrazine hydrate (12 mL, 80%) in CH2Cl2 (30 mL) at 0 °C. The mixture was stirred for 1–2 h, and the reaction progress was monitored by TLC. At the end of the reaction, the mixture was poured into cold water. The aqueous phase was extracted with CH2Cl2 (3 × 100 mL). The organic layer was combined, washed with water and brine, dried over anhydrous Na2SO4 and concentrated to give a crude product, which was subject to a silica gel column chromatography (petroleum ether-acetone 25:1, v/v) to give compound 3 as a whitish solid (4.02 g, 64%), m.p. 166–168 °C, IR (KBr, υ, cm−1): 3392, 3325, 1652, 1603, 1496, 1445, 1382, 1255, 832. 1H-NMR (CDCl3): 1.22 (d, J = 6.8 Hz, 6H, H-18 and H-19), 1.25 (s, 3H, CH3, H-16), 1.41 (s, 3H, CH3, H-15), 1.52–1.88 (m, 7H, H-2, H-3, Ha-4 and H-10), 2.27 (d, J = 12.0 Hz, 1H, H-6), 2.36 (d, J = 12.9 Hz, 1H, He-4), 2.82–2.90 (m, 3H, H-9 and H-17), 4.03 (brs, 2H, NH2), 6.89 (s, 1H, H-14), 7.01 (d, J = 8.1 Hz, 1H, H-12), 7.16 (d, J = 8.1 Hz, 1H, H-11), 8.39 (s, 1H, CONH). MS (ESI) m/z 315 ([M+H]+). Anal. Calcd for C20H30N2O: C, 76.39; H, 9.62, N, 8.91; found C, 76.51; H, 9.79; N, 8.78.

3.3.2. Gerneral Procedure for the Syntheses of N-acylhydrazone Derivatives 4a–q

To a solution of compound 3 (0.63 g, 2 mmol) in absolute EtOH (20 mL) was added 2 mmol of substituted aromatic aldehyde and 2 drops of glacial acetic acid. The mixture was refluxed for 2–3 h and the reaction was monitored by TLC. The mixture was then poured into cold water and left standing for another 4 h. The precipitate formed was filtered, washed with water and recrystalized from ethanol to afford compound 4.
Dehydroabietic acid 2-(phenylmethylene)hydrazide (4a). White powder; yield 78%; m.p. 152–156 °C; IR (KBr, υ, cm−1): 3247, 3058, 2957, 2929, 2868, 1651, 1606, 1538, 1497, 1448, 1362, 1253, 821, 756. 1H-NMR (CDCl3, 500 MHz): 1.22 (1.20) (d, J = 7.0 Hz, 6H, H-18 and H-19), 1.25 (1.24) (s, 3H, CH3, H-16), 1.40 (1.34) (s, 3H, CH3, H-15), 1.50–1.95 (m, 7H, H-2, H-3, Ha-4 and H-10), 2.27 (2.18) (d, J = 12.1 Hz, 1H, H-6), 2.34 (2.30) (d, J = 12.7 Hz, 1H, He-4), 2.74–2.96 (m, 3H, H-9 and H-17), 6.87 (6.82) (s, 1H, H-14), 7.00 (6.95) (d, J = 8.1 Hz, 1H, H-12), 7.16 (7.08) (d, J = 8.3 Hz, 1H, H-11), 7.38–7.52 (m, 3H, H-3′, H-4′ and H-5′), 7.72 (7.88) (d, J = 8.2 Hz, 2H, H-2′ and H-6′), 8.21 (8.03) (s, 1H, N=CH), 8.83 (9.29) (s, 1H, CONH). 13C-NMR (CDCl3): 16.3 (15.8), 18.6 (18.4), 21.3 (21.2), 23.9 (23.8) (C-18 and C-19), 25.1 (25.0), 29.6 (29.8), 33.3 (33.2), 37.0 (36.9), 37.1 (37.2), 37.8 (37.7), 45.4 (45.2), 47.3 (47.1), 123.9 (123.8) (C-12), 124.1 (124.0) (C-11), 126.8 (126.7) (C-14), 127.8 (127.4) (C-3′ and C-5′), 129.2 (129.1) (C-2′ and C-6′), 130.6 (130.5) (C-4′), 134.5 (134.4) (C-8), 134.9 (134.8) (C-1′), 145.8 (145.7) (C-13), 146.1 (145.8) (C=N), 146.6 (146.5) (C-7), 175.2 (176.8) (C=O). MS (ESI) m/z 403 ([M+H]+). Anal. Calcd for C27H34N2O: C, 80.55; H, 8.51, N, 6.96; found C, 80.76; H, 8.39; N, 6.84.
Dehydroabietic acid 2-[(4-methylphenyl)methylene]hydrazide (4b). White powder; yield 86%; m.p. 142–144 °C; IR (KBr, υ, cm−1): 3247, 2957, 2928, 2868, 1650, 1610, 1541, 1498, 1362, 1255, 819. 1H-NMR (CDCl3): 1.22 (1.21) (d, J = 7.0 Hz, 6H, H-18 and H-19), 1.25 (1.24) (s, 3H, CH3, H-16), 1.39 (1.34) (s, 3H, CH3, H-15), 1.50–1.95 (m, 7H, H-2, H-3, Ha-4 and H-10), 2.25 (2.19) (d, J = 12.1 Hz, 1H, H-6), 2.33 (2.30) (d, J = 12.6 Hz, 1H, He-4), 2.36 (2.44) (s, 3H, C6H4CH3), 2.78–2.95 (m, 3H, H-9 and H-17), 6.86 (6.80) (s, 1H, H-14), 7.00 (6.98) (d, J = 8.0 Hz, 1H, H-12), 7.14–7.19 (m, 3H, H-11, H-2′ and H-6′), 7.62 (7.77) (d, J = 7.0 Hz, 2H, H-3′ and H-5′), 8.15 (7.82) (s, 1H, N=CH), 8.76 (9.21) (s, 1H, CONH). 13C-NMR (CDCl3): 16.4 (15.8), 18.6 (18.4), 21.2 (21.1), 21.4 (21.5), 23.9 (23.8) (C-18 and C-19), 25.2 (25.0), 29.7 (29.8), 33.4 (33.2), 37.0 (36.9), 37.1 (37.2), 37.8 (37.7), 45.3 (45.2), 47.2 (46.8), 123.8 (123.7) (C-12), 124.0 (123.9) (C-11), 126.9 (126.8) (C-14), 127.6 (127.7) (C-2′ and C-6′), 129.3 (129.4) (C-3′ and C-5′), 131.0 (130.9) (C-1′), 134.6 (134.5) (C-8), 140.6 (140.5) (C-4′), 145.8 (145.7) (C-13), 146.8 (146.6) (C-7), 148.0 (148.4) (C=N), 174.4 (175.1) (C=O). MS (ESI) m/z 417 ([M+H]+). Anal. Calcd for C28H36N2O: C, 80.72; H, 8.71, N, 6.72; found C, 80.96; H, 8.62; N, 6.51.
Dehydroabietic acid 2-[(4-fluorophenyl)methylene]hydrazide (4c). White powder; yield 74%; m.p. 205–207 °C; IR (KBr, υ, cm−1): 3255, 2957, 2930, 2869, 1651, 1604, 1508, 1340, 1234, 835. 1H-NMR (CDCl3): 1.22 (1.21) (d, J = 7.0 Hz, 6H, H-18 and H-19), 1.25 (1.24) (s, 3H, CH3, H-16), 1.39 (1.34) (s, 3H, CH3, H-15), 1.51–1.90 (m, 7H, H-2, H-3, Ha-4 and H-10), 2.26 (2.19) (d, J = 12.1 Hz, 1H, H-6), 2.34 (2.30) (d, J = 12.9 Hz, 1H, He-4), 2.75–2.96 (m, 3H, H-9 and H-17), 6.87 (6.82) (s, 1H, H-14), 7.00 (6.95) (d, J = 8.0 Hz, 1H, H-12), 7.16 (7.08) (d, J = 8.0 Hz, 1H, H-11), 7.07 (7.21) (dd, J = 8.3, 8.1 Hz, 2H, H-3′ and H-5′), 7.71 (7.91) (dd, J = 8.3, 5.4 Hz, 2H, H-2′ and H-6′), 8.22 (8.05) (s, 1H, N=CH), 8.80 (9.28) (s, 1H, CONH). 13C-NMR (CDCl3): 16.4 (15.8), 18.6 (18.4), 21.3 (21.2), 23.9 (23.8) (C-18 and C-19), 25.2 (25.1), 29.7 (29.8), 33.4 (33.2), 37.0 (36.9), 37.1 (37.2), 37.8 (37.7), 45.3 (45.2), 47.3 (46.8), 115.6 (115.8) (2JC-F = 21.2 Hz, C-3′ and C-5′), 123.8 (123.7) (C-12), 124.0 (123.9) (C-11), 126.8 (126.7) (C-14), 129.3 (129.4) (3JC-F = 7.5 Hz, C-2′ and C-6′), 130.1 (130.0) (4JC-F = 2.5 Hz, C-1′), 134.5 (134.4) (C-8), 145.8 (145.7) (C-13), 146.6 (146.5) (C-7), 146.9 (147.4) (C=N), 164.9 (162.9) (1JC-F = 241.9 Hz, C-4′), 174.4 (174.8) (C=O). MS (ESI) m/z 421 ([M+H]+). Anal. Calcd for C27H33FN2O: C, 77.11; H, 7.91; N, 6.66; found C, 77.02; H, 8.06; N, 6.46.
Dehydroabietic acid 2-[(4-chlorophenyl)methylene]hydrazide (4d). White powder; yield 70%; m.p. 137–139 °C; IR (KBr, υ, cm−1): 3243, 2957, 2929, 2869, 1651, 1597, 1538, 1490, 1361, 1254, 1089, 822. 1H-NMR (CDCl3): 1.22 (1.21) (d, J = 7.0 Hz, 6H, H-18 and H-19), 1.25 (1.24) (s, 3H, CH3, H-16), 1.39 (1.36) (s, 3H, CH3, H-15), 1.50–1.89 (m, 7H, H-2, H-3, Ha-4 and H-10), 2.26 (2.10) (d, J = 12.1 Hz, 1H, H-6), 2.34 (2.26) (d, J = 12.9 Hz, 1H, He-4), 2.79–2.92 (m, 3H, H-9 and H-17), 6.87 (6.81) (s, 1H, H-14), 7.00 (6.95) (d, J = 7.9 Hz, 1H, H-12), 7.16 (7.07) (d, J = 7.9 Hz, 1H, H-11), 7.35 (7.52) (d, J = 8.2 Hz, 2H, H-3′ and H-5′), 7.65 (7.82) (d, J = 7.8 Hz, 2H, H-2′ and H-6′), 8.21 (7.96) (s, 1H, N=CH), 8.84 (9.37) (s, 1H, CONH). 13C-NMR (CDCl3): 16.3 (15.8), 18.5 (18.4), 21.3 (21.2), 23.9 (23.8) (C-18 and C-19), 25.2 (25.1), 29.7 (29.8), 33.4 (33.2), 37.0 (36.9), 37.1 (37.2), 37.8 (37.7), 45.3 (45.2), 47.3 (47.0), 123.8 (123.7) (C-12), 124.0 (123.9) (C-11), 126.8 (126.7) (C-14), 128.6 (128.7) (C-3′ and C-5′), 128.8 (129.0) (C-2′ and C-6′), 132.3 (132.2) (C-1′), 134.5 (134.4) (C-8), 136.1 (136.0) (C-4′), 145.7 (145.6) (C-13), 146.6 (146.5) (C-7), 146.7 (146.9) (C=N), 175.0 (175.6) (C=O). MS (ESI) m/z 437 ([M+H]+). Anal. Calcd for C27H33ClN2O: C, 74.20; H, 7.61, N, 6.41; found C, 74.51; H, 7.36; N, 6.17.
Dehydroabietic acid 2-[(4-bromophenyl)methylene]hydrazide (4e). White powder; yield 65%; m.p. 115–117 °C; IR (KBr, υ, cm−1): 3270, 2958, 2929, 2869, 1651, 1606, 1538, 1486, 1382, 1253, 1069, 820. 1H-NMR (CDCl3): 1.22 (1.21) (d, J = 7.0 Hz, 6H, H-18 and H-19), 1.25 (1.23) (s, 3H, CH3, H-16), 1.39 (1.34) (s, 3H, CH3, H-15), 1.50–1.92 (m, 7H, H-2, H-3, Ha-4 and H-10), 2.25 (2.19) (d, J = 12.1 Hz, 1H, H-6), 2.34 (2.31) (d, J = 13.0 Hz, 1H, He-4), 2.73–2.95 (m, 3H, H-9 and H-17), 6.87 (6.82) (s, 1H, H-14), 6.99 (6.94) (d, J = 8.2 Hz, 1H, H-12), 7.16 (6.07) (d, J = 8.3 Hz, 1H, H-11), 7.51 (7.69) (d, J = 8.2 Hz, 2H, H-3′ and H-5′), 7.58 (7.75) (d, J = 8.0 Hz, 2H, H-2′ and H-6′), 8.21 (8.02) (s, 1H, N=CH), 8.83 (9.41) (s, 1H, CONH). 13C-NMR (CDCl3): 16.4 (15.8), 18.6 (18.4), 21.3 (21.2), 23.9 (23.8) (C-18 and C-19), 25.2 (25.1), 29.7 (29.8), 33.4 (33.2), 37.0 (36.9), 37.1 (37.2), 37.8 (37.3), 45.3 (45.2), 47.3 (46.9), 123.9 (123.8) (C-12), 124.1 (124.0) (C-11), 124.5 (124.2) (C-4′), 126.8 (126.7) (C-14), 128.8 (128.4) (C-2′ and C-6′), 131.8 (131.6) (C-3′ and C-5′), 132.8 (132.4) (C-1′), 134.5 (134.4) (C-8), 145.7 (145.6) (C-13), 146.6 (146.5) (C-7), 146.7 (147.1) (C=N), 174.5 (174.9) (C=O). MS (ESI) m/z 481, 483 ([M+H]+). Anal. Calcd for C27H33BrN2O: C, 67.35; H, 6.91, N, 5.82; found C, 67.12; H, 6.84; N, 5.96.
Dehydroabietic acid 2-[(4-methoxylphenyl)methylene]hydrazide (4f). White powder; yield 89%; m.p. 130–132 °C; IR (KBr, υ, cm−1): 3242, 2957, 2930, 2868, 1646, 1606, 1510, 1463, 1381, 1252, 1169, 1033, 830. 1H-NMR (CDCl3): 1.22 (1.21) (d, J = 7.0 Hz, 6H, H-18 and H-19), 1.25 (1.24) (s, 3H, CH3, H-16), 1.39 (1.34) (s, 3H, CH3, H-15), 1.50–1.95 (m, 7H, H-2, H-3, Ha-4 and H-10), 2.26 (2.18) (d, J = 11.5 Hz, 1H, H-6), 2.33 (2.29) (d, J = 12.8 Hz, 1H, He-4), 2.78–2.96 (m, 3H, H-9 and H-17), 3.83 (3.89) (s, 3H, OCH3), 6.87 (6.88) (s, 1H, H-14), 6.90 (6.92) (d, J = 8.5 Hz, 2H, H-3′ and H-5′), 7.00 (7.05) (d, J = 7.0 Hz, 1H, H-12), 7.16 (7.14) (d, J = 7.0 Hz, 1H, H-11), 7.67 (7.79) (d, J = 7.8 Hz, 2H, H-2′ and H-6′), 8.12 (7.84) (s, 1H, N=CH), 8.83 (9.12) (s, 1H, CONH). 13C-NMR (CDCl3): 16.4 (15.8), 18.5 (18.4), 21.3 (21.2), 23.9 (23.8) (C-18 and C-19), 25.2 (25.1), 29.7 (29.8), 33.4 (33.2), 37.0 (36.9), 37.1 (37.2), 37.8 (37.7), 45.3 (45.2), 47.4 (47.1), 55.8 (55.6) (OCH3), 114.8 (114.7) (C-3′ and C-5′), 123.8 (123.7) (C-12), 124.0 (123.9) (C-11), 126.8 (126.7) (C-14), 128.0 (127.6) (C-1′), 131.0 (130.8) (C-2′ and C-6′), 134.6 (134.4) (C-8), 144.1 (144.5) (C=N), 145.8 (145.7) (C-13), 146.6 (146.5) (C-7), 161.2 (160.9) (C-4′), 175.7 (176.1) (C=O). MS (ESI) m/z 433 ([M+H]+). Anal. Calcd for C28H36N2O2: C, 77.74; H, 8.39, N, 6.48; found C, 77.42; H, 8.11; N, 6.68.
Dehydroabietic acid 2-[(2-hydroxyphenyl)methylene]hydrazide (4g). White powder; yield 73%; m.p. 153–155 °C; IR (KBr, υ, cm−1): 3273, 2956, 2928, 2866, 1654, 1609, 1540, 1498, 1458, 1382, 1128, 820. 1H-NMR (CDCl3): 1.21 (1.20) (d, J = 7.0 Hz, 6H, H-18 and H-19), 1.26 (1.24) (s, 3H, CH3, H-16), 1.39 (1.36) (s, 3H, CH3, H-15), 1.50–1.88 (m, 7H, H-2, H-3, Ha-4 and H-10), 2.25 (2.17) (d, J = 11.7 Hz, 1H, H-6), 2.34 (2.29) (d, J = 12.9 Hz, 1H, He-4), 2.77–2.95 (m, 3H, H-9 and H-17), 6.85 (6.80) (s, 1H, H-14), 6.96 (7.04) (d, J = 8.2 Hz, 1H, H-3′), 7.00 (6.95) (d, J = 8.0 Hz, 1H, H-12), 7.08–7.19 (m, 2H, H-11 and H-5′), 7.52–7.67 (m, 2H, H-4′ and H-6′), 8.19 (7.83) (s, 1H, N=CH), 8.84 (9.36) (s, 1H, CONH), 9.91 (10.17) (s, 1H, 2′-OH). 13C-NMR (CDCl3): 16.3 (15.8), 18.5 (18.3), 21.4 (21.2), 23.8 (23.7) (C-18 and C-19), 25.1 (25.0), 29.7 (29.8), 33.3 (33.2), 37.0 (36.9), 37.1 (37.2), 37.8 (37.7), 45.4 (45.1), 47.3 (47.1), 116.9 (116.8) (C-3′), 119.8 (119.6) (C-5′), 120.1 (119.9) (C-1′), 123.9 (123.8) (C-12), 124.1 (124.0) (C-11), 126.8 (126.7) (C-14), 131.2 (130.9) (C-6′), 131.6 (131.3) (C-4′), 134.6 (134.5) (C-8), 145.8 (145.7) (C-13), 146.6 (146.5) (C-7), 146.8 (147.3) (C=N), 157.2 (156.9) (C-2′), 175.3 (175.8) (C=O). MS (ESI) m/z 419 ([M+H]+). Anal. Calcd for C27H34N2O2: C, 77.48; H, 8.19, N, 6.69; found C, 77.69; H, 8.37; N, 6.52.
Dehydroabietic acid 2-[(3-hydroxyphenyl)methylene]hydrazide (4h). White powder; yield 86%; m.p. 135–137 °C; IR (KBr, υ, cm−1): 3276, 2957, 2930, 2869, 1652, 1602, 1539, 1455, 1382, 1362, 1230, 821. 1H-NMR (CDCl3): 1.21 (1.20) (d, J = 7.1 Hz, 6H, H-18 and H-19), 1.24 (1.23) (s, 3H, CH3, H-16), 1.37 (1.33) (s, 3H, CH3, H-15), 1.51–1.95 (m, 7H, H-2, H-3, Ha-4 and H-10), 2.26 (2.18) (d, J = 11.5 Hz, 1H, H-6), 2.32 (2.21) (d, J = 12.3 Hz, 1H, He-4), 2.78–2.92 (m, 3H, H-9 and H-17), 6.84 (6.80) (s, 1H, H-14), 6.88 (6.90) (d, J = 7.9 Hz, 1H, H-4′), 6.91–7.04 (m, 2H, H-12 and H-5′), 7.13-7.18 (m, 2H, H-11and H-6′), 7.29 (7.39) (s, 1H, H-2′), 8.01 (7.73) (s, 1H, N=CH), 8.71 (9.09) (s, 1H, CONH), 9.37 (9.72) (s, 1H, 3′-OH). 13C-NMR (CDCl3): 16.3 (15.8), 18.5 (18.4), 21.3 (21.2), 23.9 (23.8) (C-18 and C-19), 25.2 (25.1), 29.7 (29.8), 33.4 (33.2), 37.0 (36.9), 37.1 (37.2), 37.8 (37.7), 45.4 (45.2), 47.3 (47.1), 114.5 (114.2) (C-2′), 118.2 (118.1) (C-4′), 121.8 (121.6) (C-6′), 123.8 (123.7) (C-12), 124.0 (123.9) (C-11), 126.8 (126.7) (C-14), 130.6 (130.5) (C-5′), 134.5 (134.3) (C-8), 138.7 (138.5) (C-1′), 145.7 (145.6) (C-13), 146.6 (146.5) (C-7), 146.9 (147.2) (C=N), 158.6 (158.4) (C-3′), 175.5 (176.0) (C=O). MS (ESI) m/z 419 ([M+H]+). Anal. Calcd for C27H34N2O2: C, 77.48; H, 8.19, N, 6.69; found C, 77.70; H, 8.01; N, 6.45.
Dehydroabietic acid 2-[(4-hydroxyphenyl)methylene]hydrazide (4i). White powder; yield 79%; m.p. 297–298 °C; IR (KBr, υ, cm−1): 3279, 2958, 2932, 2866, 1653, 1612, 1536, 1452, 1380, 1367, 1227, 830. 1H-NMR (CDCl3): 1.22 (1.21) (d, J = 7.1 Hz, 6H, H-18 and H-19), 1.25 (1.24) (s, 3H, CH3, H-16), 1.38 (1.34) (s, 3H, CH3, H-15), 1.52–1.89 (m, 7H, H-2, H-3, Ha-4 and H-10), 2.26 (2.19) (d, J = 11.2 Hz, 1H, H-6), 2.36 (2.32) (d, J = 12.8 Hz, 1H, He-4), 2.80–2.98 (m, 3H, H-9 and H-17), 6.87 (6.81) (s, 1H, H-14), 6.95 (7.05) (d, J = 8.1 Hz, 2H, H-3′ and H-5′), 6.99 (6.94) (d, J = 8.2 Hz, 1H, H-12), 7.16 (7.08) (d, J = 8.0 Hz, 1H, H-11), 7.63 (7.79) (d, J = 8.3 Hz, 2H, H-2′ and H-6′), 8.12 (7.88) (s, 1H, N=CH), 8.79 (9.12) (s, 1H, CONH), 9.87 (9.58) (s, 1H, 4′-OH). 13C-NMR (CDCl3): 16.3 (15.8), 18.5 (18.4), 21.3 (21.2), 23.9 (23.8) (C-18 and C-19), 25.2 (25.1), 29.7 (29.8), 33.3 (33.2), 37.0 (36.9), 37.1 (37.2), 37.8 (37.7), 45.3 (45.2), 47.3 (46.9), 116.2 (116.0) (C-3′ and C-5′), 123.8 (123.7) (C-12), 124.0 (123.9) (C-11), 126.1 (126.0) (C-1′), 126.8 (126.7) (C-14), 130.6 (130.4) (C-2′ and C-6′), 134.5 (134.3) (C-8), 144.8 (145.2) (C=N), 145.7 (145.6) (C-13), 146.7 (146.5) (C-7), 160.8 (160.5) (C-4′), 175.1 (175.6) (C=O). MS (ESI) m/z 419 ([M+H]+). Anal. Calcd for C27H34N2O2: C, 77.48; H, 8.19, N, 6.69; found C, 77.31; H, 8.36; N, 6.82.
Dehydroabietic acid 2-[(4-hydroxy-3-methoxylphenyl)methylene]hydrazide (4j). White powder; yield 92%; m.p. 138–140 °C; IR (KBr, υ, cm−1): 3252, 2958, 2930, 2875, 1651, 1600, 1538, 1455, 1384, 1270, 1052, 820, 742. 1H-NMR (CDCl3): 1.22 (1.21) (d, J = 6.8 Hz, 6H, H-18 and H-19), 1.25 (1.24) (s, 3H, CH3, H-16), 1.39 (1.34) (s, 3H, CH3, H-15), 1.53–1.95 (m, 7H, H-2, H-3, Ha-4 and H-10), 2.27 (2.18) (d, J = 10.4 Hz, 1H, H-6), 2.34 (2.30) (d, J = 12.8 Hz, 1H, He-4), 2.80–2.92 (m, 3H, H-9 and H-17), 3.93 (3.99) (s, 3H, OCH3), 5.89 (brs, 1H, OH), 6.86 (6.80) (s, 1H, H-14), 6.89 (7.04) (d, J = 8.1 Hz, 1H, H-5′), 6.98 (7.12) (d, J = 8.4 Hz, 1H, H-6′), 7.00 (6.95) (d, J = 8.2 Hz, 1H, H-12), 7.17 (7.06) (d, J = 8.2 Hz, 1H, H-11), 7.50 (7.42) (s, 1H, H-2′), 8.05 (7.71) (s, 1H, N=CH), 8.76 (9.08) (s, 1H, CONH). 13C-NMR (CDCl3): 16.3 (15.9), 18.6 (18.5), 21.2(21.1), 23.9 (23.8) (C-18 and C-19), 25.1 (25.0), 29.7 (29.8), 33.4 (33.2), 37.0 (36.9), 37.1 (37.2), 37.8 (37.4), 45.3 (45.2), 47.1 (46.7), 56.1 (56.0) (OCH3), 107.7 (107.6) (C-2′), 114.0 (114.2) (C-5′), 123.5 (123.4) (C-6′), 123.8 (123.7) (C-12), 124.0 (123.9) (C-11), 126.1 (126.2) (C-1′), 126.8 (126.7) (C-14), 134.6 (134.4) (C-8), 145.7 (145.6) (C-13), 146.8 (146.7) (C-7), 147.2 (147.5) (C=N), 148.2 (148.0) (C-3′), 148.3 (148.4) (C-4′), 174.7 (175.2) (C=O). MS (ESI) m/z 449 ([M+H]+). Anal. Calcd for C28H36N2O3: C, 74.97; H, 8.09, N, 6.24; found C, 74.73; H, 7.96; N, 6.45.
Dehydroabietic acid 2-[(4-nitrophenyl)methylene]hydrazide (4k). Yellow powder; yield 71%; m.p. 148–150 °C; IR (KBr, υ, cm−1): 3255, 2956, 2927, 2869, 1657, 1602, 1523, 1473, 1382, 1249, 1172, 830. 1H-NMR (CDCl3): 1.22 (1.21) (d, J = 6.8 Hz, 6H, H-18 and H-19), 1.26 (1.24) (s, 3H, CH3, H-16), 1.41 (1.38) (s, 3H, CH3, H-15), 1.50–1.91 (m, 7H, H-2, H-3, Ha-4 and H-10), 2.24 (2.17) (d, J = 11.6 Hz, 1H, H-6), 2.35 (2.30) (d, J = 13.2 Hz, 1H, He-4), 2.75–2.96 (m, 3H, H-9 and H-17), 6.88 (6.82) (s, 1H, H-14), 7.01 (6.95) (d, J = 8.1 Hz, 1H, H-12), 7.17 (7.07) (d, J = 8.1 Hz, 1H, H-11), 7.87 (8.07) (d, J = 8.5 Hz, 2H, H-3′ and H-5′), 8.23 (8.39) (d, J = 8.5, 2H, H-2′ and H-6′), 8.44 (8.32) (s, 1H, N=CH), 9.31 (9.87) (s, 1H, CONH). 13C-NMR (CDCl3): 16.3 (15.8), 18.5 (18.4), 21.3 (21.2), 23.9 (23.8) (C-18 and C-19), 25.1 (25.0), 29.7 (29.8), 33.4 (33.2), 37.0 (36.8), 37.1 (37.2), 37.8 (37.7), 45.4 (45.3), 47.5 (46.9), 123.8 (123.6) (C-2′ and C-6′), 123.9 (123.7) (C-12), 124.0 (124.1) (C-11), 126.8 (126.7) (C-14), 127.9 (127.8) (C-3′ and C-5′), 134.3 (134.4) (C-8), 140.0 (140.1) (C-1′), 145.0 (145.5) (C=N), 145.9 (145.8) (C-13), 146.6 (146.5) (C-7), 148.5 (148.6) (C-4′), 174.6 (175.4) (C=O). MS (ESI) m/z 448 ([M+H]+). Anal. Calcd for C27H33N3O3: C, 72.46; H, 7.43, N, 9.39; found C, 72.79; H, 7.18; N, 9.12.
Dehydroabietic acid 2-[(4-chloro-3-nitrophenyl)methylene]hydrazide (4l). Yellow crystals; yield 73%; m.p. 248–250 °C; IR (KBr, υ, cm−1): 3232, 2957, 2923, 2869, 1658, 1605, 1537, 1473, 1383, 1350, 1246, 1128, 822. 1H-NMR (CDCl3): 1.22 (1.21) (d, J = 7.1 Hz, 6H, H-18 and H-19), 1.25 (1.24) (s, 3H, CH33, H-16), 1.40 (1.36) (s, 3H, CH3, H-15), 1.52–1.90 (m, 7H, H-2, H-3, Ha-4 and H-10), 2.24 (2.10) (d, J = 12.0 Hz, 1H, H-6), 2.35 (2.28) (d, J = 13.0 Hz, 1H, He-4), 2.72–2.95 (m, 3H, H-9 and H-17), 6.87 (6.81) (s, 1H, H-14), 7.00 (6.94) (d, J = 7.9 Hz, 1H, H-12), 7.17 (7.07) (d, J = 8.2 Hz, 1H, H-11), 7.55 (7.76) (d, J = 8.4 Hz, 1H, H-5′), 7.89 (8.03) (d, J = 8.1 Hz, 1H, H-6′), 8.13 (8.36) (s, 1H, H-2′), 8.44 (8.27) (s, 1H, N=CH), 9.82 (10.18) (s, 1H, CONH). 13C-NMR (CDCl3): 16.4 (15.8), 18.6 (18.4), 21.2 (21.1), 23.9 (23.8) (C-18 and C-19), 25.2 (25.1), 29.7 (29.8), 33.4 (33.2), 37.0 (36.9), 37.1 (37.2), 37.8 (37.4), 45.3 (45.2), 47.2 (46.8), 123.5 (123.2) (C-2′), 123.8 (123.7) (C-12), 124.0 (123.9) (C-11), 126.3 (125.9) (C-1′), 126.8 (126.7) (C-14), 129.2 (129.0) (C-5′), 131.9 (131.5) (C-6′), 134.4 (134.2) (C-4′), 134.6 (134.5) (C-8), 145.7 (145.6) (C-13), 146.6 (146.5) (C-7), 146.8 (147.2) (C=N), 147.9 (147.7) (C-3′), 174.3 (174.7) (C=O). MS (ESI) m/z 482 ([M+H]+). Anal. Calcd for C27H32ClN3O3: C, 67.28; H, 6.69, N, 8.72; found C, 67.43; H, 6.91; N, 8.51.
Dehydroabietic acid 2-[(2-hydroxy-5-nitrophenyl)methylene]hydrazide (4m). Yellow powder; yield 68%; m.p. 158–160 °C; IR (KBr, υ, cm−1): 3269, 2959, 2928, 2869, 1655, 1610, 1513, 1478, 1383, 1340, 1247, 1174, 822. 1H-NMR (CDCl3): 1.22 (1.21) (d, J = 6.8 Hz, 6H, H-18 and H-19), 1.25 (1.24) (s, 3H, CH3, H-16), 1.41 (1.35) (s, 3H, CH3, H-15), 1.50–1.92 (m, 7H, H-2, H-3, Ha-4 and H-10), 2.18 (2.10) (d, J = 11.8 Hz, 1H, H-6), 2.36 (2.24) (d, J = 13.0 Hz, 1H, He-4), 2.80–2.92 (m, 3H, H-9 and H-17), 6.87 (6.82) (s, 1H, H-14), 7.01 (6.95) (d, J = 7.8 Hz, 1H, H-12), 7.06 (7.10) (d, J = 8.9 Hz, 1H, H-3′), 7.16 (7.08) (d, J = 8.2 Hz, 1H, H-11), 8.15 (8.04) (s, 1H, H-6′), 8.17 (8.09) (d, J = 8.0 Hz, 1H, H-4′), 8.51 (8.48) (s, 1H, N=CH), 9.03 (9.76) (s, 1H, CONH), 10.02 (s, 1H, 2′-OH). 13C-NMR (CDCl3): 16.2 (15.8), 18.4 (18.3), 21.3 (21.2), 23.9 (23.8) (C-18 and C-19), 25.1 (25.0), 29.6 (29.7), 33.3 (33.2), 37.0 (36.9), 37.1 (37.2), 37.7 (37.6), 45.4 (45.2), 47.3 (47.1), 117.5 (117.4) (C-3′), 117.8 (117.9) (C-1′), 123.7 (123.6) (C-12), 123.9 (123.8) (C-11), 126.4 (126.3) (C-6′), 126.7 (126.6) (C-14), 126.8 (127.0) (C-4′), 134.2 (134.1) (C-8), 140.0 (139.9) (C-5′), 145.8 (145.7) (C-13), 146.5 (146.3) (C-7), 147.7 (148.1) (C=N), 163.7 (163.8) (C-2′), 175.3 (175.8) (C=O). MS (ESI) m/z 464 ([M+H]+). Anal. Calcd for C27H33N3O4: C, 69.95; H, 7.18, N, 9.06; found C, 69.78; H, 7.26; N, 8.92.
Dehydroabietic acid 2-[(5-chloro-2-hydroxyphenyl)methylene]hydrazide (4n). White powder; yield 73%; m.p. 133–134 °C; IR (KBr, υ, cm−1): 3269, 2957, 2930, 2869, 1650, 1611, 1530, 1478, 1383, 1345, 1272, 952, 821. 1H-NMR (CDCl3): 1.22 (1.21) (d, J = 6.8 Hz, 6H, H-18 and H-19), 1.25 (1.24) (s, 3H, CH3, H-16), 1.40 (1.36) (s, 3H, CH3, H-15), 1.48–1.90 (m, 7H, H-2, H-3, Ha-4 and H-10), 2.17 (2.08) (d, J = 11.8 Hz, 1H, H-6), 2.35 (2.30) (d, J = 12.9 Hz, 1H, He-4), 2.72–2.95 (m, 3H, H-9 and H-17), 6.88 (6.81) (s, 1H, H-14), 6.93 (6.96) (d, J = 8.8 Hz, 1H, H-3′), 7.01 (7.07) (d, J = 8.0 Hz, 1H, H-12), 7.14–7.25 (m, 3H, H-11, H-4′ and H-6′), 8.37 (8.18) (s, 1H, N=CH), 8.83 (8.68) (s, 1H, 2′-OH), 9.84 (10.13) (s, 1H, CONH). 13C-NMR (CDCl3): 16.3 (15.8), 18.5 (18.4), 21.3 (21.2), 23.9 (23.8) (C-18 and C-19), 25.1 (25.0), 29.6 (29.8), 33.4 (33.2), 37.0 (36.9), 37.1 (37.2), 37.8 (37.7), 45.5 (45.3), 47.3 (46.9), 118.6 (118.5) (C-3′), 118.7 (118.8) (C-1′), 123.7 (123.6) (C-5′), 123.9 (123.8) (C-12), 124.0 (124.1) (C-11), 126.9 (126.8) (C-14), 129.7 (129.6) (C-6′), 131.3 (131.1) (C-4′), 134.4 (134.5) (C-8), 145.9 (145.8) (C-13), 146.6 (146.5) (C-7), 148.9 (149.2) (C=N), 157.0 (157.1) (C-2′), 174.7 (175.2) (C=O). MS (ESI) m/z 453 ([M+H]+). Anal. Calcd for C27H33ClN2O2: C, 71.58; H, 7.34, N, 6.18; found C, 71.79; H, 7.51; N, 6.02.
Dehydroabietic acid 2-[(furan-2-yl)methylene]hydrazide (4o). White powder; yield 77%; m.p. 127–129 °C; IR (KBr, υ, cm−1): 3247, 2957, 2929, 2868, 1652, 1610, 1532, 1474, 1387, 1248, 1134, 952, 820, 742. 1H-NMR (CDCl3): 1.21 (1.20) (d, J = 7.0 Hz, 6H, H-18 and H-19), 1.26 (1.24) (s, 3H, CH3, H-16), 1.45 (1.38) (s, 3H, CH3, H-15), 1.48–1.90 (m, 7H, H-2, H-3, Ha-4 and H-10), 2.23 (2.16) (d, J = 11.9 Hz, 1H, H-6), 2.33 (2.29) (d, J = 12.0 Hz, 1H, He-4), 2.75–2.95 (m, 3H, H-9 and H-17), 6.60 (6.48) (dd, J = 3.6, 1.8 Hz, 1H, H-4′), 6.86 (6.81) (s, 1H, H-14), 6.73 (6.58) (dd, J = 3.6, 0.8 Hz, 1H, H-3′), 6.99 (6.94) (d, J = 8.0 Hz, 1H, H-12), 7.16 (7.06) (d, J = 8.1 Hz, 1H, H-11), 7.58 (7.52) (dd, J = 1.8, 0.8 Hz, 1H, H-5′), 8.45 (7.89) (s, 1H, N=CH), 9.67 (10.11) (s, 1H, CONH). 13C-NMR (CDCl3): 16.4 (15.8), 18.5 (18.4), 21.4 (21.2), 23.9 (23.8) (C-18 and C-19), 25.2 (25.1), 29.7 (29.8), 33.4 (33.2), 37.0 (36.9), 37.1 (37.2), 37.8 (37.7), 45.5 (45.3), 47.3 (46.8), 112.7 (112.5) (C-3′), 113.4 (113.2) (C-4′), 123.7 (123.6) (C-12), 123.9 (123.8) (C-11), 126.8 (126.7) (C-14), 134.2 (134.1) (C-8), 137.2 (137.6) (C=N), 145.4 (145.2) (C-5′), 145.8 (145.7) (C-13), 146.6 (146.5) (C-7), 149.0 (149.6) (C-2′), 175.3 (175.9) (C=O). MS (ESI) m/z 393 ([M+H]+). Anal. Calcd for C25H32N2O2: C, 76.49; H, 8.22, N, 7.14; found C, 76.33; H, 8.05; N, 7.36.
Dehydroabietic acid 2-[(5-nitrofuran-2-yl)methylene]hydrazide (4p). White powder; yield 77%; m.p. 127–129 °C; IR (KBr, υ, cm−1): 3256, 2959, 2932, 2866, 1651, 1607, 1522, 1465, 1382, 1241, 1136, 823, 755; 1H-NMR (CDCl3): 1.21 (1.20) (d, J = 6.8 Hz, 6H, H-18 and H-19), 1.25 (1.24) (s, 3H, CH3, H-16), 1.42 (1.36) (s, 3H, CH3, H-15), 1.46–1.92 (m, 7H, H-2, H-3, Ha-4 and H-10), 2.21 (2.15) (d, J = 11.7 Hz, 1H, H-6), 2.32 (2.28) (d, J = 12.6 Hz, 1H, He-4), 2.78–2.90 (m, 3H, H-9 and H-17), 6.86 (6.80) (s, 1H, H-14), 7.00 (6.94) (d, J = 8.1 Hz, 1H, H-12), 7.28 (7.42) (d, J = 3.8 Hz, 1H, H-3′), 7.17 (7.05) (d, J = 8.1 Hz, 1H, H-11), 7.72 (7.85) (d, J = 3.8 Hz, 1H, H-4′), 8.39 (8.11) (s, 1H, N=CH), 9.51 (9.85) (s, 1H, CONH). 13C-NMR (CDCl3): 16.3 (15.8), 18.5 (18.4), 21.3 (21.2), 23.9 (23.8) (C-18 and C-19), 25.2 (25.1), 29.7 (29.8), 33.4 (33.2), 37.0 (36.9), 37.1 (37.2), 37.7 (37.6), 45.4 (45.3), 47.3 (47.0), 114.6 (114.5) (C-3′), 115.1 (115.0) (C-4′), 123.8 (123.7) (C-12), 124.0 (123.8) (C-11), 126.8 (126.7) (C-14), 134.3 (134.2) (C-8), 137.8 (138.2) (C=N), 145.8 (145.7) (C-13), 146.6 (146.5) (C-7), 151.5 (151.2) (C-5′), 152.0 (151.8) (C-2′), 175.1 (175.6) (C=O). MS (ESI) m/z 438 ([M+H]+). Anal. Calcd for C25H31N3O4: C, 68.63; H, 7.14, N, 9.60; found C, 68.48; H, 7.21; N, 9.45.
Dehydroabietic acid 2-[(pyridin-2-yl)methylene]hydrazide (4q). White powder; yield 74%; m.p. 238–240 °C; IR (KBr, υ, cm−1): 3260, 2957, 2930, 2869, 1652, 1611, 1528, 1470, 1382, 1271, 1132, 820, 776; 1H-NMR (CDCl3): 1.22 (1.21) (d, J = 7.0 Hz, 6H, H-18 and H-19), 1.25 (1.24) (s, 3H, CH3, H-16), 1.41 (1.36) (s, 3H, CH3, H-15), 1.48–1.95 (m, 7H, H-2, H-3, Ha-4 and H-10), 2.22 (2.16) (d, J = 11.6 Hz, 1H, H-6), 2.36 (2.29) (d, J = 13.0 Hz, 1H, He-4), 2.75–2.90 (m, 3H, H-9 and H-17), 6.87 (6.82) (s, 1H, H-14), 6.99 (6.95) (d, J = 8.0 Hz, 1H, H-12), 7.16 (7.06) (d, J = 8.1 Hz, 1H, H-11), 7.46 (7.31) (dd, J = 7.8, 4.5 Hz, 1H, H-5′), 7.87 (7.66) (t, J = 7.6 Hz, 1H, H-4′), 8.23 (8.38) (d, J = 7.6 Hz, 1H, H-3′), 8.54 (8.65) (d, J = 4.5 Hz, 1H, H-6′), 8.58 (8.42) (s, 1H, N=CH), 9.16 (9.58) (s, 1H, CONH). 13C-NMR (CDCl3): 16.3 (15.8), 18.6 (18.4), 21.3 (21.2), 23.9 (23.8) (C-18 and C-19), 25.2 (25.1), 29.7 (29.8), 33.4 (33.2), 37.0 (36.9), 37.1 (37.2), 37.8 (37.7), 45.4 (45.2), 47.3 (47.1), 120.2 (119.8) (C-3′), 123.9 (123.8) (C-12), 124.1 (124.0) (C-11), 124.6 (124.5) (C-5′), 126.8 (126.7) (C-14), 134.6 (134.5) (C-8), 137.5 (137.3) (C-4′), 145.8 (145.7) (C-13), 146.2 (146.4) (C=N), 146.6 (146.5) (C-7), 149.8 (149.5) (C-6′), 153.7 (153.8) (C-2′), 175.7 (176.0) (C=O). MS (ESI) m/z 404 ([M+H]+). Anal. Calcd for C26H33N3O: C, 77.38; H, 8.24, N, 10.41; found C, 77.48; H, 8.11; N, 10.32.

3.4. Antibacterial Studies

The antibacterial activities of the newly synthesized compounds 4a–q were evaluated against four test bacteria: Bacillus subtilis CGMCC1.3343, Escherichia coli CGMCC1.3373, Pseudomonas fluorescens CGMCC1.1802 and Staphylococcus aureus CGMCC1.2465. The four bacteria were obtained from China General Microbiological Culture Collection Center (CGMCC), China. The antibacterial activity was assessed in terms of minimum inhibitory concentrations (MICs) by a modified microdilution method [22]. Compounds were dissolved in DMSO and serial double dilutions of each compound (50 μL) were prepared in 96 well micro-trays. The same amount of test microorganism suspension in Martin’s broth (~105 colony forming unit (CFU)/mL) was added to each well to give final concentrations ranging from 250 to 0.45 μg/mL. Amikacin sulfate was co-assayed as positive control, and DMSO was used as negative control. After incubation at 37 ′C for 24 h, the trays were examined for the growth for the test microorganisms. The MIC was defined as the lowest concentrations of compound at which there was no visual turbidity due to microbial growth. All assays were performed in duplicate.

4. Conclusions

In this study, a series of new N-acylhydrazone derivatives 4a–q of dehydroabietic acid were synthesized and characterized in approach of new antibacterial agents. All the compounds were evaluated for their in vitro antibacterial activities against four bacteria. The MIC results indicated that the activities of the investigated compounds were influenced by the physicochemical properties of the substituent at hydrazone moiety. Compounds with fluoro, chloro and nitro substituents exhibited pronounced antibacterial activities, among which the nitrofuranyl derivative 4p showed strongest activity against two Gram-positive bacteria. The results highlight these new N-acylhydrazone derivatives as potential leads for the further investigation on new antibacterial drug candidates.

Acknowledgements

The authors are grateful to the National Natural Science Foundation of China for financial support (Project: 31000273 and 30972316). This work was also supported by a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).
  • Sample Availability: Samples of the newly synthesized compounds (4a-q) are available from the authors.

References and Notes

  1. Aksoy, D.Y.; Unal, S. New antimicrobial agents for the treatment of Gram-positive bacterial infections. Clin. Microbiol. Infect. 2008, 14, 411–420. [Google Scholar]
  2. Kumar, D.; Judge, V.; Narang, R.; Sangwan, S.; De Clercq, E.; Balzarini, J.; Narasimhan, B. Benzylidene/2-chlorobenzylidene hydrazides: Synthesis, antimicrobial activity, QSAR studies and antiviral evaluation. Eur. J. Med. Chem. 2010, 45, 2806–2816. [Google Scholar]
  3. Rollas, S.; Küçükgüzel, S.G. Biological activities of hydrazone derivatives. Molecules 2007, 12, 1910–1939. [Google Scholar]
  4. ink, R.; Kovač, A.; Tomašić, T.; Rupnik, V.; Boniface, A.; Bostock, J.; Chopra, I.; Blanot, D.; Mašič, L.P.; Gobec, S.; et al. Synthesis and biological evaluation of N-acylhydrazones as inhibitors of MurC and MurD ligases. ChemMedChem 2008, 3, 1362–1370. [Google Scholar] [CrossRef]
  5. Masunari, A.; Tavares, L.C. A new class of nifuroxazide analogues: Synthesis of 5-nitrothiophene derivatives with antimicrobial activity against multidrug-resistant Staphylococcus aureus. Bioorg. Med. Chem. 2007, 15, 4229–4236. [Google Scholar]
  6. Chornous, V.A.; Bratenko, M.K.; Vovk, M.V.; Sidorchuk, I.I. Synthesis and antimicrobial activity of pyrazole-4-carboxylic acid hydrazides and N-(4-Pyrazoyl)hydrazones of aromatic and heteroaromatic aldehydes. Pharm. Chem. J. 2001, 35, 203–205. [Google Scholar]
  7. Melnyk, P.; Leroux, V.; Sergheraert, C.; Grellier, P. Design, synthesis and in vitro antimalarial activity of an acylhydrazone library. Bioorg. Med. Chem. Lett. 2006, 16, 31–35. [Google Scholar]
  8. Tian, B.H.; He, M.Z.; Tan, Z.W.; Tang, S.X.; Hewlett, I.; Chen, S.G.; Jin, Y.X.; Yang, M. Synthesis and antiviral evaluation of new N-acylhydrazones containing glycine residue. Chem. Biol. Drug Des. 2011, 77, 189–198. [Google Scholar]
  9. Cui, Z.N.; Li, Y.; Ling, Y.; Huang, J.A.; Cui, J.R.; Wang, R.Q.; Yang, X.L. New class of potent antitumor acylhydrazone derivatives containing furan. Eur. J. Med. Chem. 2010, 45, 5576–5584. [Google Scholar]
  10. da Silva, Y.K.C.; Augusto, C.V.; Barbosa, M.L.D.; Melo, G.M.D.; de Queiroz, A.C.; Dias, T.D.M.F.; Bispo, W.; Barreiro, E.J.; Lima, L.M.; Alexandre-Moreira, M.S. Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates. Bioorg. Med. Chem. 2010, 18, 5007–5015. [Google Scholar]
  11. Dimmock, J.R.; Vashishtha, S.C.; Stables, J.P. Anticonvulsant properties of various acetylhydrazones, oxamoylhydrazones and semicarbazones derived from aromatic and unsaturated carbonyl compounds. Eur. J. Med. Chem. 2000, 35, 241–248. [Google Scholar]
  12. Ergenç, N.; Günay, N.S.; Demirdamar, R. Synthesis and antidepressant evaluation of new 3-phenyl-5-sulfonamidoindole derivatives. Eur. J. Med. Chem. 1998, 33, 143–148. [Google Scholar]
  13. Zapata-Sudo, G.; Pereira, S.L.; Beiral, H.J.V.; Kummerle, A.E.; Raimundo, J.M.; Antunes, F.; Sudo, R.; Barreiro, E.J.; Fraga, C.A.M. Pharmacological characterization of (3-thienylidene)-3,4-methylenedioxybenzoylhydrazide: A novel muscarinic agonist with antihypertensive profile. Am. J. Hypertens. 2010, 23, 135–141. [Google Scholar]
  14. Lee, W.S.; Kim, J.R.; Han, J.M.; Jang, K.C.; Sok, D.E.; Jeong, T.S. Antioxidant activities of abietane diterpenoids isolated from Torreya nucifera leaves. J. Agric. Food Chem. 2006, 54, 5369–5374. [Google Scholar]
  15. Chao, K.P.; Hua, K.F.; Hsu, H.Y.; Su, Y.C.; Chang, S.T. Anti-inflammatory activity of sugiol, a diterpene isolated from Calocedrus formosana bark. Planta Med. 2005, 71, 300–305. [Google Scholar]
  16. Savluchinske-Feio, S.; Curto, M.J.M.; Gigante, B.; Roseiro, J.C. Antimicrobial activity of resin acid derivatives. Appl. Microbiol. Biotechnol. 2006, 72, 430–436. [Google Scholar]
  17. Córdova, I.; León, L.G.; León, F.; San Andrés, L.; Luis, J.G.; Padrón, J.M. Synthesis and antiproliferative activity of novel sugiol β-amino alcohol analogs. Eur. J. Med. Chem. 2006, 41, 1327–1332. [Google Scholar]
  18. Gigante, B.; Santos, C.; Silva, A.M.; Curto, M.J.M.; Nascimento, M.S.J.; Pinto, E.; Pedro, M.; Cerqueira, F.; Pinto, M.M.; Duarte, M.P.; et al. Catechols from abietic acid: Synthesis and evaluation as bioactive compounds. Bioorg. Med. Chem. 2003, 11, 1631–1638. [Google Scholar]
  19. Fonseca, T.; Gigante, B.; Marques, M.M.; Gilchrist, T.L.; De Clercq, E. Synthesis and antiviral evaluation of benzimidazoles, quinoxalines and indoles from dehydroabietic acid. Bioorg. Med. Chem. 2004, 12, 103–112. [Google Scholar]
  20. Kang, M.S.; Hirai, S.; Goto, T.; Kuroyanagi, K.; Lee, J.Y.; Uemura, T.; Ezaki, Y.; Takahashi, N.; Kawada, T. Dehydroabietic acid, a phytochemical, acts as ligand for PPARs in macrophages and adipocytes to regulate inflammation. Biochem. Biophys. Res. Commun. 2008, 369, 333–338. [Google Scholar]
  21. Sepúlveda, B.; Astudillo, L.; Rodríguez, J.A.; Yáñez, T.; Theoduloz, C.; Schmeda-Hirschmann, G. Gastroprotective and cytotoxic effect of dehydroabietic acid derivatives. Pharmacol. Res. 2005, 52, 429–437. [Google Scholar]
  22. Gu, W.; Wang, S.F. Synthesis and antimicrobial activities of novel 1H-dibenzo[a,c]carbazoles from dehydroabietic acid. Eur. J. Med. Chem. 2010, 45, 4692–4696. [Google Scholar]
  23. Su, G.F.; Guan, Y.F.; Huang, W.Y.; Wang, H.S.; Pan, Y.M. Synthesis and crystal structure of 2-(4-decarboxydehydroabietyl)-5-p-tolyl-[1,3,4]-oxadiazole. Chinese J. Struct. Chem. 2009, 28, 881–885. [Google Scholar]
  24. Shingalapur, R.V.; Hosamani, K.M.; Keri, R.S.; Hugar, M.H. Derivatives of benzimidazole pharmacophore: Synthesis, anticonvulsant, antidiabetic and DNA cleavage studies. Eur. J. Med. Chem. 2010, 45, 1753–1759. [Google Scholar]
  25. Lee, S.; Jung, K.Y.; Park, J.; Cho, J.H.; Kim, Y.C.; Chang, S. Synthesis of potent chemical inhibitors of dynamin GTPase. Bioorg. Med. Chem. Lett. 2010, 20, 4858–4864. [Google Scholar]
  26. Han, C.R.; Song, Z.Q.; Shang, S.B.; Gao, H. Synthesis and characterization of novel dehydroabietyl-1,3,4-oxadiazoles (in Chinese). Xiandai Huagong 2007, 27, 42–44. [Google Scholar]
  27. Syakaev, V.V.; Podyachev, S.N.; Buzykin, B.I.; Latypov, S.K.; Habicher, W.D.; Konovalov, A.I. NMR study of conformation and isomerization of aryl- and heteroarylaldehyde 4-tert-butylphenoxyacetylhydrazones. J. Mol. Struct. 2006, 788, 55–62. [Google Scholar]
  28. Nakka, M.; Begum, M.S.; Varaprasad, B.F.M.; Reddy, L.V.; Bhattacharya, A.; Helliwell, M.; Mukherjee, A.K.; Beevi, S.S.; Mangamoori, L.N.; Mukkanti, K.; et al. Naproxen and ibuprofen based acyl hydrazone derivatives: Synthesis, structure analysis and cytotoxicity studies. J. Chem. Pharm. Res. 2010, 2, 393–409. [Google Scholar]
  29. Palla, G.; Predieri, G.; Domiano, P.; Vignali, C.; Turner, W. Conformational behaviour and E/Z isomerization of N-acyl and N-aroylhydrazones. Tetrahedron 1986, 42, 3649–3654. [Google Scholar]
  30. Unsal-Tan, O.; Ozden, K.; Rauk, A.; Balkan, A. Synthesis and cyclooxygenase inhibitory activities of some N-acylhydrazone derivatives of isoxazolo[4,5-d]pyridazin-4(5H)-ones. Eur. J. Med. Chem. 2010, 45, 2345–2352. [Google Scholar]
  31. Plech, T.; Wujec, M.; Siwek, A.; Kosikowska, U.; Malm, A. Synthesis and antimicrobial activity of thiosemicarbazides, s-triazoles and their Mannich bases bearing 3-chlorophenyl moiety. Eur. J. Med. Chem. 2011, 46, 241–248. [Google Scholar]
  32. Kossakowski, J.; Krawiecka, M.; Kuran, B.; Stefańska, J.; Wolska, I. Synthesis and preliminary evaluation of the antimicrobial activity of selected 3-benzofurancarboxylic acid derivatives. Molecules 2010, 15, 4737–4749. [Google Scholar]
  33. Upadhyay, A.; Srivastava, S.K.; Srivastava, S.D. Conventional and microwave assisted synthesis of Some new N-[(4-oxo-2-substituted aryl-1, 3-thiazolidine)-acetamidyl]-5- nitroindazoles and its antimicrobial activity. Eur. J. Med. Chem. 2010, 45, 3541–3548. [Google Scholar]
  34. Küçükgüzel, S.G.; Mazi, A.; Sahin, F.; Öztürk, S.; Stables, J. Synthesis and biological activities of diflunisal hydrazide-hydrazones. Eur. J. Med. Chem. 2003, 38, 1005–1013. [Google Scholar] [CrossRef]
  35. Viodé, C.; Bettache, N.; Cenas, N.; Krauth-Siegel, R.; Chauvière, G.; Bakalara, N.; Périé, J. Enzymatic reduction studies of nitroheterocycles. Biochem. Pharmacol. 1999, 57, 549–557. [Google Scholar]
  36. Quillardet, P.; Arrault, X.; Michel, V.; Touati, E. Organ-targeted mutagenicity of nitrofurantoin in Big Blue transgenic mice. Mutagenesis 2006, 21, 305–311. [Google Scholar]
  37. Bartel, L.C.; de Mecca, M.M.; Castro, J.A. Nitroreductive metabolic activation of some carcinogenic nitro heterocyclic food contaminants in rat mammary tissue cellular fractions. Food Chem. Toxicol. 2009, 47, 140–144. [Google Scholar]
  38. Chung, M.C.; Bosquesi, P.L.; dos Santos, J.L. A prodrug approach to improve the physico-chemical properties and decrease the genotoxicity of nitro compounds. Curr. Pharm. Design 2011, 17, 3515–3526. [Google Scholar]
  39. Halbrook, N.J.; Lawrence, R.V. The isolation of dehydroabietic acid from disproportionated rosin. J. Org. Chem. 1966, 31, 4246–4247. [Google Scholar]
  40. Sheldrick, G.M. SHELX-97; University of Gǒttingen: Gǒttingen, Germany, 1997. [Google Scholar]

Share and Cite

MDPI and ACS Style

Gu, W.; Wu, R.; Qi, S.; Gu, C.; Si, F.; Chen, Z. Synthesis and Antibacterial Evaluation of New N-acylhydrazone Derivatives from Dehydroabietic Acid. Molecules 2012, 17, 4634-4650. https://doi.org/10.3390/molecules17044634

AMA Style

Gu W, Wu R, Qi S, Gu C, Si F, Chen Z. Synthesis and Antibacterial Evaluation of New N-acylhydrazone Derivatives from Dehydroabietic Acid. Molecules. 2012; 17(4):4634-4650. https://doi.org/10.3390/molecules17044634

Chicago/Turabian Style

Gu, Wen, Rongrong Wu, Shilong Qi, Chenhai Gu, Fanjunnan Si, and Zhuhui Chen. 2012. "Synthesis and Antibacterial Evaluation of New N-acylhydrazone Derivatives from Dehydroabietic Acid" Molecules 17, no. 4: 4634-4650. https://doi.org/10.3390/molecules17044634

APA Style

Gu, W., Wu, R., Qi, S., Gu, C., Si, F., & Chen, Z. (2012). Synthesis and Antibacterial Evaluation of New N-acylhydrazone Derivatives from Dehydroabietic Acid. Molecules, 17(4), 4634-4650. https://doi.org/10.3390/molecules17044634

Article Metrics

Back to TopTop